HC Wainwright & Co. analyst Edward White maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $8 to $6.
Robitussin Recall: Here Are The Products Impacted And What You Need To Know
Haleon PLC (NYSE: HLN) announced a product recall of some of its Robitussin brand cough syrups.
What Happened: A microbial contamination in Robitussin cough syrups could potentially cause life-threatening events in immunocompromised customers.
